Meeting
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase I results of the phase I/II study of pembrolizumab in combination with binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer.
Authors
Saranya Chumsri
Mayo Clinic, Jacksonville, FL
Saranya Chumsri, Mei-Yin Polley, Pulkit Mathur, Aline Reis, Kathleen S. Tenner, Morgan Weidner, Pooja Advani, Alvaro Moreno-Aspitia, Edith A. Perez, Keith L. Knutson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Immune Checkpoints and Stimulatory Receptors
Clinical Trial Registration Number
NCT03106415
Citation
J Clin Oncol 38, 2020 (suppl 5; abstr 78)
Abstract #
78
Poster Bd #
A11
Abstract Disclosures
Similar Posters
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase I/II trial of pembrolizumab in combination with binimetinib in unresectable locally advanced or metastatic triple negative breast cancer.
First Author: Saranya Chumsri
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Casper: A phase I, open-label, dose finding study of calaspargase pegol-mnkl (cala) in combination with cobimetinib (cobi) in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).
First Author: Charles D. Lopez
Poster
2022 ASCO Annual Meeting
A phase I/II trial evaluating the safety and efficacy of eribulin in combination with copanlisib in patients with metastatic triple-negative breast cancer (TNBC).
First Author: Nusayba Ali Bagegni
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase I study of hydroxychloroquine plus binimetinib in patients with metastatic pancreatic cancer (the HOPE trial).
First Author: Rishi Surana